Linked Life Data

2966140

Source:http://linkedlifedata.com/resource/pubmed/id/2966140

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1988-5-27
pubmed:abstractText
Teicoplanin, a new glycopeptide antibiotic, has a serum half-life of 47 h and excellent activity against Gram-positive bacteria, including methicillin resistant staphylococci, making it a potentially useful drug for cardiac surgical prophylaxis. In two prospective randomized studies, we have compared it with a broad spectrum regimen of an aminoglycoside and flucloxacillin. In the first trial, teicoplanin (400 mg on induction of anaesthesia and 200 mg 24 h later), was compared with tobramycin (80 mg tds for three days) and flucloxacillin (500 mg qds for 5 days) in 314 patients. Teicoplanin prophylaxis resulted in a significantly greater number of sternal wound infections (P less than 0.01), due to Gram-positive bacteria. Furthermore, Gram-negative bacteria were responsible for more respiratory and urinary infections after teicoplanin prophylaxis. In the second trial, comprising 203 patients, the teicoplanin dose regimen was changed to three doses of 400 mg but this did not improve the rates of infection.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0305-7453
pubmed:author
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
213-23
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Antibiotic prophylaxis in cardiac surgery: a prospective comparison of two dosage regimens of teicoplanin with a combination of flucloxacillin and tobramycin.
pubmed:affiliation
Department of Cardiothoracic Surgery, Middlesex College Hospital, London, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't